Nephron 1992:61:337-338
R Cantiia S. Manganoa ¿V/. Masinib A. Limidoa C. Cwvettib C. DeFilippob
Prevalence of Antibodies against Hepatitis C Virus in a Dialysis Unit
a Dialysis and b Immunohematology Senäces, S. Anionio Abate Hospital, Gallarate, Italy
Abstract Anti-HCV was tested in 77 uremic patients, 48 on hemodialysis (HD), 29 on CAPD, by immunoenzymatic 1st and 2nd generation assays (ELISA I. II) and 4-antigen (4-RIBA) immublotting. The investigation was extended to the staff (n = 29) and to HC'V-positive patients' families (n = 30). The prevalence using 2nd generation tests was double (21%) that in 1st generation tests (11%). A greater incidence in the HD than in the CAPD group (23 vs. 17%) and a highly significative correlation to dialytic age were observed. No one among the sanitary personnel and only 2 family members were found HCV positive, suggesting a low infectivity via the parenteral inevident route. Extracorporeal circulation and particularly the exposure time to the treatment seem to be the main risk factors.
The achievement of tests to identify anti-HCV antibody allowed to find out a high but variable incidence of this infection among dialysis patients. The purpose of our work was to verify anti-HCV pre valence in our Dialysis Unit, and to inquire the correlation to incidental risk factors. Patients and Methods Sera from 77 patients, 48 on hemodialysis (HD) and 29 on CAPD, were tested. The investigation was extended to the staff of the Unit (6 doctors, 23 nurses) and to HCV-positive patients’ families (30 mem bers, 6 of whom sexually active). 3,000 donors of the Transfusion Service were taken as control group. Immunoenzymatic 1st and 2nd generation assays (ELISA 1,11) and 4-antigen (4-RIBA) immublotting tests (Ortho-Chiron Diagnostic Co) were employed. Eventual correlations to HBcAb. blood tranfusions, ALT levels > 45 U l/m l in the previous 24 months were considered.
Results The prevalence of HCV positivity in the control group was 0.8%. 8 of 77 patients turned out positive for anti-HCV on ELISA I, with a 10% prevalence. Among the remaining 69 patients, 8 were positive with ELISA 11, raising the overall prevalence to 21%. All HCV-positive sera were con firmed by 4-RI BA test. II (68%) of the 16 HCV-positive patients were treated with HD and 5 (32%) with CAPD. Totally 23% of patients (11 of 48) and 17% (5 of 29) of CAPD patients came out to be HCV positive. The average dialytic age of HCV-negative patients was significantly lower than that of HCV-positive patients (40.3 ±37.5 months versus63 ±43.2 months: p Vandelli L, Medici G, Savazzi A: Infezione da virus C in pazienti emodializzati: aspetti clinici ed organizzativi. G Ital Nefrol 1991:8(suppt I): 345.
3 Esteban J. Gonzales A, Hernandez JN: Evolution of antibody to hepatitis C virus in a study of transfusion-associated hepatitis. N Engl J Med 1990:343:1107. 4 Ideo G. Bellazzi G: Intrafamiliar transmission of HCV. Lancet 1990:335:102.
C aniu/M angano/M asini/Lim ido/Crovetti/ De Filippo
Anti-HCV Seroprevalence in a Dialysis Unit
Downloaded by: Univ. of California Santa Barbara 128.111.121.42 - 3/4/2018 7:49:03 AM
Table 1. Rela tionship between anti-HCV and time on dialysis
R Cantiia S. Manganoa ¿V/. Masinib A. Limidoa C. Cwvettib C. DeFilippob
Prevalence of Antibodies against Hepatitis C Virus in a Dialysis Unit
a Dialysis and b Immunohematology Senäces, S. Anionio Abate Hospital, Gallarate, Italy
Abstract Anti-HCV was tested in 77 uremic patients, 48 on hemodialysis (HD), 29 on CAPD, by immunoenzymatic 1st and 2nd generation assays (ELISA I. II) and 4-antigen (4-RIBA) immublotting. The investigation was extended to the staff (n = 29) and to HC'V-positive patients' families (n = 30). The prevalence using 2nd generation tests was double (21%) that in 1st generation tests (11%). A greater incidence in the HD than in the CAPD group (23 vs. 17%) and a highly significative correlation to dialytic age were observed. No one among the sanitary personnel and only 2 family members were found HCV positive, suggesting a low infectivity via the parenteral inevident route. Extracorporeal circulation and particularly the exposure time to the treatment seem to be the main risk factors.
The achievement of tests to identify anti-HCV antibody allowed to find out a high but variable incidence of this infection among dialysis patients. The purpose of our work was to verify anti-HCV pre valence in our Dialysis Unit, and to inquire the correlation to incidental risk factors. Patients and Methods Sera from 77 patients, 48 on hemodialysis (HD) and 29 on CAPD, were tested. The investigation was extended to the staff of the Unit (6 doctors, 23 nurses) and to HCV-positive patients’ families (30 mem bers, 6 of whom sexually active). 3,000 donors of the Transfusion Service were taken as control group. Immunoenzymatic 1st and 2nd generation assays (ELISA 1,11) and 4-antigen (4-RIBA) immublotting tests (Ortho-Chiron Diagnostic Co) were employed. Eventual correlations to HBcAb. blood tranfusions, ALT levels > 45 U l/m l in the previous 24 months were considered.
Results The prevalence of HCV positivity in the control group was 0.8%. 8 of 77 patients turned out positive for anti-HCV on ELISA I, with a 10% prevalence. Among the remaining 69 patients, 8 were positive with ELISA 11, raising the overall prevalence to 21%. All HCV-positive sera were con firmed by 4-RI BA test. II (68%) of the 16 HCV-positive patients were treated with HD and 5 (32%) with CAPD. Totally 23% of patients (11 of 48) and 17% (5 of 29) of CAPD patients came out to be HCV positive. The average dialytic age of HCV-negative patients was significantly lower than that of HCV-positive patients (40.3 ±37.5 months versus63 ±43.2 months: p Vandelli L, Medici G, Savazzi A: Infezione da virus C in pazienti emodializzati: aspetti clinici ed organizzativi. G Ital Nefrol 1991:8(suppt I): 345.
3 Esteban J. Gonzales A, Hernandez JN: Evolution of antibody to hepatitis C virus in a study of transfusion-associated hepatitis. N Engl J Med 1990:343:1107. 4 Ideo G. Bellazzi G: Intrafamiliar transmission of HCV. Lancet 1990:335:102.
C aniu/M angano/M asini/Lim ido/Crovetti/ De Filippo
Anti-HCV Seroprevalence in a Dialysis Unit
Downloaded by: Univ. of California Santa Barbara 128.111.121.42 - 3/4/2018 7:49:03 AM
Table 1. Rela tionship between anti-HCV and time on dialysis
